HICM-188 clinical trials
How each study uses HICM-188 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HICM-188 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- HiCM-188 therapy
- 2
Studies by the year they started
3 studies that test it; most in 2026 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
HELP Therapeutics Co., Ltd. (3) · HELP Therapeutics, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test HICM-188, phase 3 first.
- Jun 2027A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)Phase 3 · HELP Therapeutics Co., Ltd.
- Nov 2026Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart FailurePhase 1/2 · HELP Therapeutics Co., Ltd.
Studies
Open first, then newest update. How each study uses HICM-188 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryNot yet recruitingPhase 1/2HELP Therapeutics, Inc.NCT07646210Written as HiCM-188 Cells
- A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)RecruitingPhase 3HELP Therapeutics Co., Ltd.NCT07496372Written as HiCM-188 therapy
- hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart DiseaseNot yet recruitingPhase 1/2HELP Therapeutics Co., Ltd.NCT07471698Written as HiCM-188 Chitosan Patch
- Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart FailureActive, not recruitingPhase 1/2HELP Therapeutics Co., Ltd.NCT06340048Written as HiCM-188 therapy